Mirova US’s Takeda Pharmaceutical TAK Stock Holding History

Mirova US’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,301	Closed	-$25K	–	31
2019 Q4	$25K	Buy	+1,301	New	+$24.9K	﹤0.01%	28

Other funds holding TAK

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mirova US's TAK Position: Q1 2020 in Review

Mirova US sold out of Takeda Pharmaceutical (TAK) in Q1 2020, closing a stake of 1,301 shares — an estimated $25K sold.

Mirova US first reported a position in TAK in Q4 2019 and held it in 1 quarter. The position peaked at $25K in Q4 2019. 312 funds tracked by Wall St. Rank hold TAK as of Q1 2020.

Mirova US reported no remaining Takeda Pharmaceutical position as of Q1 2020 after selling out during the quarter.
Mirova US sold 1,301 Takeda Pharmaceutical shares in Q1 2020, an estimated $25K.
Mirova US first reported a position in Takeda Pharmaceutical in Q4 2019 and held it in 1 quarter.
Mirova US's Takeda Pharmaceutical position peaked at $25K in Q4 2019.
312 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2020.

Based on Mirova US's 13F filing for Q1 2020, filed 13 May 2020.